MedTrace Logo

Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

NCT03033446 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of liver-localised radioembolization and nivolumab on liver cancer.

Conditions

Interventions

RADIATION

Y-90 Radioembolization

Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan

DRUG

Nivolumab

21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks

Sponsors & Collaborators

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • David Wai-Meng TAI, MD · National Cancer Centre, Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-20
Primary Completion
2019-08-31
Completion
2023-04-26

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03033446 on ClinicalTrials.gov